Evidence map›Paper›PMID 27974459›Full record

ArticleThe Journal of biological chemistry2017

Identification of the RNA Pyrophosphohydrolase RppH of Helicobacter pylori and Global Analysis of Its RNA Targets.

Thorsten Bischler, Ping-Kun Hsieh, Marcus Resch, Quansheng Liu, Hock Siew Tan, Patricia L Foley, Anika Hartleib, Cynthia M Sharma, Joel G Belasco

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07682415 (A Single-arm, Multicenter, Prospective Phase II Clinical Trial of Delayed Fixed-duration Combination With Sotoraclax Following Zanubrutinib Induction in Patients With CLL/SLL), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07682415 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Single-arm, Multicenter, Prospective Phase II Clinical Trial of Delayed Fixed-duration Combination With Sotoraclax Following Zanubrutinib Induction in Patients With CLL/SLL: Stop Trial 2.0

TypeinterventionalSponsorYi ShuhuaRan2026 to 2034Enrolled60ConditionsCLL / SLLArms12 cycles of zanubrutinib followed by 12 cycles of zanubrutinib in combination with sonrotoclax, zanubrutinib maintenance until disease progression
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. A distinct RNA recognition mechanism governs NpProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  8. Riboregulation in the Major Gastric PathogenFrontiers in microbiology · 2021
    Review
  9. Review of current diagnostic methods and advances inWorld journal of gastroenterology · 2019
    Review
  10. Review
  11. Article
  12. Regulatory Tools for Controlling Gene Expression in Cyanobacteria.Advances in experimental medicine and biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Thorsten BischlerFrom the Research Center for Infectious Diseases, University of Würzburg, Josef-Schneider-Strasse 2/D15, 97080 Würzburg, Germany; the Institute of Molecular Infection Biology, University of Würzburg, Josef-Schneider-Strasse 2/D15, 97080 Würzburg, Germany and.
Ping-Kun Hsiehthe Kimmel Center for Biology and Medicine at the Skirball Institute and the Department of Microbiology, New York University School of Medicine, New York, New York 10016.
Marcus ReschFrom the Research Center for Infectious Diseases, University of Würzburg, Josef-Schneider-Strasse 2/D15, 97080 Würzburg, Germany; the Institute of Molecular Infection Biology, University of Würzburg, Josef-Schneider-Strasse 2/D15, 97080 Würzburg, Germany and.
Quansheng Liuthe Kimmel Center for Biology and Medicine at the Skirball Institute and the Department of Microbiology, New York University School of Medicine, New York, New York 10016.
Hock Siew Tanthe Institute of Molecular Infection Biology, University of Würzburg, Josef-Schneider-Strasse 2/D15, 97080 Würzburg, Germany and.
Patricia L Foleythe Kimmel Center for Biology and Medicine at the Skirball Institute and the Department of Microbiology, New York University School of Medicine, New York, New York 10016.
Anika HartleibFrom the Research Center for Infectious Diseases, University of Würzburg, Josef-Schneider-Strasse 2/D15, 97080 Würzburg, Germany; the Institute of Molecular Infection Biology, University of Würzburg, Josef-Schneider-Strasse 2/D15, 97080 Würzburg, Germany and.
Cynthia M SharmaFrom the Research Center for Infectious Diseases, University of Würzburg, Josef-Schneider-Strasse 2/D15, 97080 Würzburg, Germany; the Institute of Molecular Infection Biology, University of Würzburg, Josef-Schneider-Strasse 2/D15, 97080 Würzburg, Germany and. Electronic address: cynthia.sharma@uni-wuerzburg.de.
Joel G Belascothe Kimmel Center for Biology and Medicine at the Skirball Institute and the Department of Microbiology, New York University School of Medicine, New York, New York 10016. Electronic address: joel.belasco@med.nyu.edu.
University of Würzburg · DENew York University · US

Funding

INFECTIOUS DISEASES &BASIC MICROBIOLOGICAL MECHANISMST32AI007180 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEISER, JEFFREY NEAL · 1985 to 2022
$8.9M
Prokaryotic RNA Metabolism - Resubmission - 1R01GM035769 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BELASCO, JOEL G · 1986 to 2021
$7.1M
Molecular Basis for mRNA Decay in Bacteria - summer supplementR01GM112940 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SERGANOV, ALEXANDER · 2015 to 2023
$3.2M
NIAID NIH HHS T32 AI007180NIGMS NIH HHS R01 GM035769NIGMS NIH HHS R01 GM112940
6 · The paper itself

Abstract

RNA degradation is crucial for regulating gene expression in all organisms. Like the decapping of eukaryotic mRNAs, the conversion of the 5'-terminal triphosphate of bacterial transcripts to a monophosphate can trigger RNA decay by exposing the transcript to attack by 5'-monophosphate-dependent ribonucleases. In both biological realms, this deprotection step is catalyzed by members of the Nudix hydrolase family. The genome of the gastric pathogen Helicobacter pylori, a Gram-negative epsilonproteobacterium, encodes two proteins resembling Nudix enzymes. Here we present evidence that one of them, HP1228 (renamed HpRppH), is an RNA pyrophosphohydrolase that triggers RNA degradation in H. pylori, whereas the other, HP0507, lacks such activity. In vitro, HpRppH converts RNA 5'-triphosphates and diphosphates to monophosphates. It requires at least two unpaired nucleotides at the 5' end of its substrates and prefers three or more but has only modest sequence preferences. The influence of HpRppH on RNA degradation in vivo was examined by using RNA-seq to search the H. pylori transcriptome for RNAs whose 5'-phosphorylation state and cellular concentration are governed by this enzyme. Analysis of cDNA libraries specific for transcripts bearing a 5'-triphosphate and/or monophosphate revealed at least 63 potential HpRppH targets. These included mRNAs and sRNAs, several of which were validated individually by half-life measurements and quantification of their 5'-terminal phosphorylation state in wild-type and mutant cells. These findings demonstrate an important role for RppH in post-transcriptional gene regulation in pathogenic Epsilonproteobacteria and suggest a possible basis for the phenotypes of H. pylori mutants lacking this enzyme.

Indexed as

Acid Anhydride HydrolasesBacterial ProteinsGene Expression Regulation, BacterialHelicobacter pyloriRNA, BacterialRNA, MessengerRNA StabilityAcid Anhydride HydrolasesBacterial ProteinsRNA, BacterialRNA, Messengerdeep sequencinggene regulationHelicobacter pyloriNudixRNA degradationRNA modificationRNA-protein interactionRNA turnover

Identifiers

PMID27974459
PMCPMC5290964
OpenAlexW2565854398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.